Pacific Biosciences of California
Pacific Biosciences of California Inc, operating as PacBio, is an American biotechnology equipment company delivering long-read DNA sequencing systems. The company designs, manufactures, and markets Single Molecule, Real-Time (SMRT) and short-read sequencing platforms, including the Revio and Onso sequencing systems, alongside sequencing reagent kits. Main revenue drivers consist of commercial sales of high-throughput DNA sequencing instruments, single-use chemical reagent kits, and technical maintenance service contracts. PacBio serves academic research institutes, genome centers, agricultural biotechnology firms, clinical diagnostic labs, and biopharmaceutical corporations globally. The company holds a world-dominant market position in highly accurate long-read DNA sequencing technology. Headquartered in Menlo Park, California, Pacific Biosciences of California Inc is listed on the Nasdaq Stock Market.
2 of the funds FundTelligence covers report a position in Pacific Biosciences of California.
- Legal name
- PACIFIC BIOSCIENCES OF CALIFORNIA
- Sector
- Health Care
- Country
- United States
- Funds holding it
- 2
- Exposure themes
- Genomics & Profiling, Precision Medicine & Genomics, Sequencing
Funds holding Pacific Biosciences of California
- BlackRock iShares Healthcare Innovation UCITS ETF — BlackRock · 0.07 % (full portfolio disclosed, October 2026)
- BlackRock iShares NASDAQ US Biotechnology UCITS ETF — BlackRock · 0.05 % (full portfolio disclosed, October 2026)